Monday, July 28, 2014

Roth starts CorMedix at buy

Roth starts CorMedix at buy

July 24, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and $3 price target. The stock closed at $1.94 on Wednesday. “The impetus for our buy rating is the potential of the company’s Neutrolin compound to drive revenues and ultimately profits,” writes analyst Scott Henry. Neutrolin is approved in Europe and […]

Roth starts PTC Therapeutics at buy

Roth starts PTC Therapeutics at buy

July 7, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “buy” rating and $34 price target. The stock was quoted at $26.04 at mid-day on Monday. PTC is pioneering the development of small molecules for the treatment of rare genetic disorders and other chronic conditions. “The conditional approval for ataluren in the […]

Roth ups EnteroMedics price target to $5

Roth ups EnteroMedics price target to $5

June 18, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” EnteroMedics (NASDAQ:ETRM) to $5 from $3 after the FDA’s Gastroenterology-Urology Device Advisory Panel voted that the benefits of the company’s Maestro System outweigh the risks by a margin of six-to-two, with one abstention. Shares of EnteroMedics closed at $1.52 on Tuesday. On safety, the […]

Roth ups TG Therapeutics target to $20

Roth ups TG Therapeutics target to $20

June 16, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” TG Therapeutics (NASDAQ:TGTX) to $20 from $15 after the company announced data from its Phase 2 study of TG-1101 & ibrutinib combination in r/r CLL or MCL. The stock closed at $8.82 on Friday. The first ten evaluable patients demonstrated an ORR of 90% […]

Roth resumes coverage of Conatus Pharma at buy

Roth resumes coverage of Conatus Pharma at buy

June 13, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a ‘buy” rating and $19 price target. The stock closed at $7.71 on Thursday. Conatus’ sole asset, emricasan, is a first-in-class, oral pan-caspase inhibitor with a unique dual mechanism of action: inhibiting both the inflammation and apoptosis of liver disease. “We believe emricasan’s mechanism allows […]

Roth starts MacroGenics at buy

Roth starts MacroGenics at buy

June 9, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated of MacroGenics (NASDAQ:MGNX) with a “buy” rating and $28 price target, saying the “era of molecular engineering is upon us.” The stock closed at $20.03 on Friday. MacroGenics is pioneering immune-modulation-based therapies through its ability to engineer antibodies at the molecular level. “We anticipate up to six (currently two) […]

Roth adds TG Therapeutics to focus list

Roth adds TG Therapeutics to focus list

May 22, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has added “buy-rated” TG Therapeutics (NASDAQ:TGTX) to its focus list, saying the remainder of 2014 could be transformational for TG with upcoming data catalysts and visibility from the competitive landscape. “Beyond monotherapy data with TG-1101 and TGR-1202, we believe the potential ‘match made in heaven’ combo data (’1101 + Imbruvica and […]

Roth starts NeoGenomics at buy

Roth starts NeoGenomics at buy

May 12, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of NeoGenomics Laboratories (NASDAQ:NEO) with a “buy” rating and $6 price target. The stock closed at $3.04 on Friday. NeoGenomics is a high-complexity oncology reference lab, which is on the “brink of significant revenue acceleration despite reimbursement headwinds,” writes analyst Debjit Chattopadhyay. Shares of NeoGenomics are currently trading […]

Roth and Cantor start Applied Genetics at buy

Roth and Cantor start Applied Genetics at buy

April 21, 2014 by · Leave a Comment 

Tweet Roth Capital Partners and Cantor Fitzgerald have initiated coverage of Applied Genetics Technologies (NASDAQ:AGTC) at “buy” ratings, with price targets of $25 and $21, respectively. The stock closed at $14.08 on Thursday. Applied Genetics is a gene therapy company with a focus on orphan ophthalmology and lung disorders. The company uses its adeno-like virus […]

Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

April 14, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to […]

Next Page »

Email Newsletters with Constant Contact
Google+